Mice lacking bone sialoprotein (BSP) lose bone after ovariectomy and display skeletal site-specific response to intermittent PTH treatment

Endocrinology

Volumn 151, Issue 11, 2010, Pages 5103-5113

  Wade Gueye, Ndéye Marième ^a   Boudiffa, Maya ^a   Laroche, Norbert ^a   Vanden Bossche, Arnaud ^a   Fournier, Carole ^a   Aubin, Jane E ^b   Vico, Laurence ^a   Lafage Proust, Marie Hélène ^a   Malaval, Luc ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE SIALOPROTEIN; CALCIUM; DENTIN MATRIX PROTEIN 1; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; DMP1 PROTEIN, MOUSE; GLYCOPROTEIN; INTEGRIN BINDING SIALOPROTEIN; INTEGRIN-BINDING SIALOPROTEIN; MEPE PROTEIN, MOUSE; PHOSPHOPROTEIN; SCLEROPROTEIN; SIALOGLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; GENOTYPE; HYPOCALCEMIA; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM; TRABECULAR BONE; ANALYSIS OF VARIANCE; ANIMAL; BONE; DRUG EFFECT; FEMALE; GENETICS; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENOTYPE; GLYCOPROTEINS; HYPERPARATHYROIDISM; HYPOCALCEMIA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; OVARIECTOMY; PARATHYROID HORMONE; PHENOTYPE; PHOSPHOPROTEINS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALOGLYCOPROTEINS;

EID: 78049500524     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0091     Document Type: Article

References (39)

1. Fisher LW, Fedarko NS 2003 Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44(Suppl 1):33-40
2. Ogbureke KU, Fisher LW 2004 Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664-670
3. Ogbureke KU, Fisher LW 2005 Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155-166
4. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS 2008 Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212-226
5. Sodek J, Ganss B, McKee MD 2000 Osteopontin. Crit Rev Oral Biol Med 11:279-303
6. Ganss B, Kim RH, Sodek J 1999 Bone sialoprotein. Crit Rev Oral Biol Med 10:79-98
7. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, Hruska KA 2003 Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14:173-189
8. Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M 2001 Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193:399-404
9. Yoshitake H, Rittling SR, Denhardt DT, Noda M 1999 Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156-8160
10. Kitahara K, Ishijima M, Rittling SR, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M 2003 Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144:2132-2140 (Pubitemid 36543353)
11. Malaval L, Wade-Guéye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amédée J, Vico L, Rossant J, Aubin JE 2008 Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205:1145-1153
12. Oldberg A, Franzén A, Heinegård D, Pierschbacher M, Ruoslahti E 1988 Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 263:19433-19436 (Pubitemid 19016420)
13. Hunter GK, Goldberg HA 1994 Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem J 302(Pt 1):175-179
14. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA 2007 Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41:462-473
15. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC 1993 Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 90:8424-8428 (Pubitemid 23277681)
16. Silver J, Kilav R, Sela-Brown A, Naveh-Many T 2000 Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol 14:626-628
17. Valverde P, Zhang J, Fix A, Zhu J, Ma W, Tu Q, Chen J 2008 Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice. J Bone Miner Res 23:1775-1788
18. Bonnelye E, Kung V, Laplace C, Galson DL, Aubin JE 2002 Estrogen receptor-related receptor alpha impinges on the estrogen axis in bone: potential function in osteoporosis. Endocrinology 143:3658-3670
19. Meng XW, Liang XG, Birchman R, Wu DD, Dempster DW, Lindsay R, Shen V 1996 Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res 11:421-429
20. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM 2003 Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33:372-379
21. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
22. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326-339
23. Iida-Klein A, Hughes C, Lu SS, Moreno A, Shen V, Dempster DW, Cosman F, Lindsay R 2006 Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. J Bone Miner Res 21:274-282 (Pubitemid 43265293)
24. Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL 2006 Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 39:260-267 (Pubitemid 43851364)
25. Wang Y, Nishida S, Boudignon BM, Burghardt A, Elalieh HZ, Hamilton MM, Majumdar S, Halloran BP, Clemens TL, Bikle DD 2007 IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 22:1329-1337 (Pubitemid 351339678)
26. Wang Y, Sakata T, Elalieh HZ, Munson SJ, Burghardt A, Majumdar S, Halloran BP, Bikle DD 2006 Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I. J Endocrinol 189:279-287
27. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816
28. Goltzman D 2008 Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473:218-224
29. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253 (Pubitemid 40863814)
30. Alos N, Ecarot B 2005 Downregulation of osteoblast Phex expression by PTH. Bone 37:589-598
31. Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau I 2005 Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5:356-357
32. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941
33. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY 2006 Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262-272
34. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE 2003 Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14:77-81
35. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502
36. Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW 2007 Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 40:391-398
37. Noda M, Rodan GA 1989 Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol 108:713-718 (Pubitemid 19065866)
38. Kasugai S, Zhang Q, Overall CM, Wrana JL, Butler WT, Sodek J 1991 Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Miner 13:235-250
39. Yang R, Gerstenfeld LC 1996 Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts. J Biol Chem 271:29839-29846